Status:
ENROLLING_BY_INVITATION
Iterative Design Trial to Assess Dietary Supplements and Other Aging-targeted Therapies
Lead Sponsor:
Atria Research and Global Health Institute (ARGHI)
Conditions:
Aging
Longevity
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This is a multi-cohort, open-label, adaptive trial designed to evaluate the safety, tolerability, and biological effects of dietary supplements and other aging-targeted therapies. Cohort 1 is a singl...
Eligibility Criteria
Inclusion
- Adults aged 18 to 75
- Patients without known significant organ dysfunction, based on standard blood tests within the last year
Exclusion
- Patients taking any immunomodulatory medications that the investigator or treating physician believe may alter the immune response to the study agent (e.g. biologic antibodies, immunosuppressants)
- Patients actively receiving any therapy that, in the determination of the investigator, may impact the effect of the study agent.
- Patients who, in the opinion of the treating investigator, will not be able to follow treatment and defined follow-up
- Pregnancy
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2031
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT07202403
Start Date
September 1 2025
End Date
September 1 2031
Last Update
October 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Atria Research and Global Health Institute
New York, New York, United States, 10022